Australien - engelsk - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - epirubicin hydrochloride, quantity: 200 mg - injection - excipient ingredients: lactose monohydrate - epirubicin hypdrochloride for injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - epirubicin hydrochloride is indicated for the treatment of the following: - transitional cell bladder cancer - early breast cancer - metastatic/advanced breast cancer - gastro-esophageal cancer - head and neck cancer - primary hepatocellular cancer - acute leukemia - non-small-cell lung cancer - small-cell lung cancer - non-hodgkin?s lymphoma - hodgkin?s lymphoma - multiple myeloma - ovarian cancer - pancreatic cancer - hormone-refractory prostatic cancer - rectal cancer - soft-tissue and bone sarcomas

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - pharmorubicin has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of: ? breast cancer ? gastric cancer ? ovarian cancer ? small cell lung cancer ? lymphoma (non-hodgkin?s lymphoma) ? advanced/metastatic soft tissue sarcoma ? superficial bladder cancer (tis, ta) in bladder cancer, pharmorubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grade 2 and 3).

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - pharmorubicin has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of: ? breast cancer ? gastric cancer ? ovarian cancer ? small cell lung cancer ? lymphoma (non-hodgkin?s lymphoma) ? advanced/metastatic soft tissue sarcoma ? superficial bladder cancer (tis, ta) in bladder cancer, pharmorubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grade 2 and 3).

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid - the drug is indicated for the treatment of the following: - transitional cell bladder cancer - early breast cancer - metastatic/advanced breast cancer - gastro-esophageal cancer - head and neck cancer - primary hepatocellular cancer - acute leukemia - non-small cell lung cancer - small cell lung cancer - non-hodgkin?s lymphoma - hodgkin?s lymphoma - multiple myeloma - ovarian cancer - pancreatic cancer - hormone-refractory prostatic cancer - rectal cancer - soft tissue and bone sarcomas

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid - the drug is indicated for the treatment of the following: - transitional cell bladder cancer - early breast cancer - metastatic/advanced breast cancer - gastro-esophageal cancer - head and neck cancer - primary hepatocellular cancer - acute leukemia - non-small cell lung cancer - small cell lung cancer - non-hodgkin?s lymphoma - hodgkin?s lymphoma - multiple myeloma - ovarian cancer - pancreatic cancer - hormone-refractory prostatic cancer - rectal cancer - soft tissue and bone sarcomas

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

actavis australia pty ltd - epirubicin hydrochloride -

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - farmorubicina tm cs (epirubicin hydrochloride) has a significant therapeutic response in several neoplasms such as: breast carcinoma, malignant lymphomas, soft tissue sarcomas, gastric carcinoma, liver carcinoma, pancreatic cancer, rectum-sigmoid carcinoma, cervical-facial carcinoma, pulmonary carcinoma, ovarian carcinoma and leukemias. farmorubicina tm cs by intravesical instillation is indicated to treat superficial bladder carcinoma (of transitional cells, carcinoma in situ) and for prophylaxis of recurrences after trans-urethral resection.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - farmorubicintm cs (epirubicin hydrochloride) has a significant therapeutic response in several neoplasms, among them: breast carcinoma, malignant lymphomas, soft tissue sarcomas, gastric carcinoma, liver cancer, pancreatic cancer, rectum-sigmoid carcinoma, carcinoma of the cervix-facial region, pulmonary carcinoma, ovarian carcinoma and leukemia?s. farmorubicintm cs by intravesical instillation is indicated in treatment of superficial bladder carcinomas (transitional cell carcinoma, in situ carcinoma) and in the prophylaxis of relapses after transurethral resection.